STOCK TITAN

Compugen Ltd - CGEN STOCK NEWS

Welcome to our dedicated news page for Compugen (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Compugen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Compugen's position in the market.

Rhea-AI Summary
Compugen announced the online publication of a peer-reviewed paper unveiling the potential of COM503, a differentiated antibody targeting the IL-18 pathway for cancer immunotherapy. The paper highlights the potent immune stimulation and anti-tumor effects of this novel approach, showcasing the company's computational target discovery expertise. Collaborating with Gilead Sciences, Compugen aims to accelerate the development of COM503 towards IND filing and a Phase 1 study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
none
-
Rhea-AI Summary
Compugen (CGEN) to participate in upcoming investor conferences in April, showcasing its clinical-stage cancer immunotherapy and computational target discovery expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
conferences
-
Rhea-AI Summary
Compugen Ltd. (Nasdaq: CGEN) has been selected to give two oral presentations at the Keystone Symposium on Cancer Immunotherapy. The presentations will focus on novel insights into T Cell Biology and progress in drugging the TIGIT and VISTA pathways. The company aims to transform patient lives through its computational target discovery platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.44%
Tags
none
Rhea-AI Summary
Compugen Ltd. (Nasdaq: CGEN) to present data on its immuno-oncology pipeline at the AACR annual meeting, showcasing progress in addressing immunotherapy resistance through novel targets and therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
conferences
-
Rhea-AI Summary
Compugen Ltd. reported positive financial results for Q4 and full year 2023, highlighted by a partnership with Gilead for a preclinical immuno-oncology program. The company's strong balance sheet and extended cash runway bode well for future growth, with upcoming milestones in 2024. Financially, Compugen saw a significant increase in revenues, with a healthy cash position and no debt. However, research and development expenses rose, leading to a net loss for the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.56%
Tags
-
Rhea-AI Summary
Compugen Ltd. (CGEN) to participate in a fireside chat at Leerink Partners Global Biopharma Conference. The event will take place on March 11, 2024, in Miami Beach, Florida, at 11:20 AM ET. A live webcast and replay will be accessible on Compugen's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.4%
Tags
conferences
Rhea-AI Summary
Compugen Ltd. announced the release of its fourth quarter and full year 2023 financial results on March 5, 2024. The company, known for its computational target discovery in cancer immunotherapy, will host a conference call to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Compugen Ltd. appoints Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024, succeeding Henry Adewoye, M.D. Michelle brings extensive clinical development experience to lead the advancement of cancer immunotherapy programs, including the COM503 Phase 1 study partnered with Gilead Sciences. Henry's departure marks the end of his 6-year tenure with Compugen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
management
-
Rhea-AI Summary
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) is entitled to receive a $10 million milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
Rhea-AI Summary
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) has announced that it has regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550(a)(2). The company received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC, confirming that it evidenced a closing bid price at or greater than $1.00 per ordinary share for the last 10 consecutive business days from December 19, 2023, to January 3, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.86%
Tags
none
Compugen Ltd

Nasdaq:CGEN

CGEN Rankings

CGEN Stock Data

202.23M
84.69M
5.38%
13.71%
2.34%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Israel
Holon

About CGEN

compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. the company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its pipeline program. the company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its pipeline program and various forms of research and discovery agreements, in both cases providing compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. compugen’s wholly-owned u.s. subsidiary located in south san francisco is developing monoclonal antib